On Dec. 8, 2023, bluebird bio announced the U.S. commercial launch of its LYFGENIA’ (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved gene therapy for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs).

The LYFGENIA launch builds on bluebird’s demonstrated success delivering ex vivo gene therapies to patients in the U.S. and included outcomes-based contract offerings for payers, as well as a personalized patient support program.